Cell Free DNA (cfDNA) Testing Market Report 2026

The cell free dna (cfdna) testing market size has grown exponentially in recent years. It will grow from $10.84 billion in 2025 to $13.42 billion in 2026 at a compound annual growth rate (CAGR) of 23.8%. The growth in the historic period can be attributed to increasing prevalence of cancer diagnostics, adoption of non-invasive testing methods, expansion of prenatal screening programs, improvements in sequencing technologies, growing clinical acceptance of liquid biopsy.

The cell free dna (cfdna) testing market size is expected to see exponential growth in the next few years. It will grow to $28.81 billion in 2030 at a compound annual growth rate (CAGR) of 21%. The growth in the forecast period can be attributed to increasing investments in precision oncology, rising demand for early cancer detection, expansion of transplant monitoring applications, growing adoption of personalized medicine, increasing integration of AI-driven genomic analysis. Major trends in the forecast period include increasing adoption of liquid biopsy diagnostics, rising use of ngs-based cfdna analysis, growing demand for non-invasive prenatal testing, expansion of oncology monitoring applications, enhanced integration of bioinformatics platforms.

The increasing prevalence of cancer is anticipated to drive the growth of the cell-free DNA (cfDNA) testing market in the coming years. Cancer is a diverse group of diseases marked by the uncontrolled proliferation and spread of abnormal cells within the body. These abnormal cells can invade and damage healthy tissues and, if left unmanaged, can cause severe harm. The growing incidence of cancer is attributed to aging populations, lifestyle changes, environmental factors, and improvements in detection and diagnostic technologies. cfDNA testing enables the identification of cancer-associated genetic mutations at an early stage, often before clinical symptoms develop. This supports timely intervention, improving patient outcomes and survival rates by detecting cancer in its earliest phases. For instance, in February 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, more than 35 million new cancer cases are projected globally by 2050, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the growing burden of cancer is fueling the expansion of the cell-free DNA (cfDNA) testing market.

Major companies operating in the cell-free DNA (cfDNA) testing market are emphasizing the development of innovative technologies, such as liquid biopsy assays, that provide enhanced sensitivity, specificity, and efficiency for detecting cancer-related mutations and genetic alterations. Liquid biopsy tests are diagnostic methods that enable clinicians to analyze circulating cell-free DNA shed by tumor cells, supporting the development of personalized and targeted treatment strategies. For instance, in May 2023, Laboratory Corporation of America Holdings (Labcorp), a US-based life sciences company, introduced Labcorp Plasma Focus, a liquid biopsy test designed for patients with advanced or metastatic solid tumors. This test analyzes circulating cell-free DNA (cfDNA) obtained from a routine blood draw, offering a minimally invasive approach with rapid results. It improves access to precision oncology by identifying clinically actionable biomarkers across multiple cancer types, including non-small cell lung, colorectal, breast, esophageal, gastroesophageal junction, gastric cancers, and melanoma.

In February 2024, Veracyte Inc., a US-based genomic diagnostics company, acquired C2i Genomics for an undisclosed sum. Through this acquisition, Veracyte seeks to broaden its oncology testing capabilities, accelerate the development of precision oncology solutions, enhance genomic insights for cancer management, and strengthen its overall diagnostics portfolio. C2i Genomics is a US-based healthcare technology company specializing in cell-free DNA (cfDNA) testing.

Major companies operating in the cell free dna (cfdna) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen N.V., Exact Sciences Corporation, Bio-Techne Corporation, Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Invitae Corporation, Foundation Medicine Inc., Guardant Health Inc., Integrated DNA Technologies Inc., Caris Life Sciences Inc., Twist Bioscience Corporation, Adaptive Biotechnologies Corporation, Biodesix Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems Inc., Circulogene Theranostics LLC.

North America was the largest region in the cell-free DNA (cfDNA) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell free dna (cfdna) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell free dna (cfdna) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cell free DNA testing market by increasing costs of imported sequencing instruments, reagents, sample preparation kits, and bioinformatics hardware used in cfDNA analysis. Diagnostic laboratories in North America and Europe are most affected due to reliance on imported NGS platforms, while Asia-Pacific faces cost pressure on testing infrastructure expansion. These tariffs are raising testing costs and slowing technology upgrades. However, they are also encouraging domestic reagent production, regional sequencing platform development, and localized diagnostic manufacturing capabilities.

The cell free dna (cfdna) testing market research report is one of a series of new reports that provides cell free dna (cfdna) testing market statistics, including cell free dna (cfdna) testing industry global market size, regional shares, competitors with a cell free dna (cfdna) testing market share, detailed cell free dna (cfdna) testing market segments, market trends and opportunities, and any further data you may need to thrive in the cell free dna (cfdna) testing industry. This cell free dna (cfdna) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell-free DNA (cfDNA) testing is a non-invasive diagnostic technique that examines DNA fragments freely circulating in the bloodstream. This testing method is widely used in liquid biopsy procedures and enables the detection and analysis of genetic mutations and variations without requiring a conventional tissue biopsy.

The main products of the cell-free DNA (cfDNA) testing market include donor-derived cell-free DNA, circulating cell-free tumor DNA, and cell-free fetal DNA. Donor-derived cell-free DNA refers to cfDNA originating from a transplanted donor organ or tissue that circulates in the recipient’s blood. The different platforms used include next-generation sequencing (NGS), rPCR and multiplex PCR, qPCR and dPCR, and other technologies, which support applications such as oncology, non-invasive prenatal testing (NIPT), gynecology, transplantation, and other disease conditions.

The cell-free DNA (cfDNA) testing market consists of revenue entities earned by providing services such as liquid biopsy for cancer detection and monitoring, transplant rejection monitoring, and non-invasive prenatal testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell-free DNA (cfDNA) testing market also includes sales of products such as digital PCR systems, automated nucleic acid extraction systems, real-time PCR instruments, and library preparation systems for NGS. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.